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1. Introduction 
Cancer of the oral cavity, also known as “oral cavity cancer” or more simply “oral cancer”, 
affects the tongue, gingiva, floor of mouth, palate, tonsils and oropharynx.1, 2 However, the 
most common form of oral cancer, oral squamous cell carcinoma (OSCC), can affect any 
tissue lined with oral mucosal epithelium.2, 3 Oral cancer is one of the most common 
malignancies  in the world, ranking eighth and thirteenth for males and females 
respectively.1 Typically, patients with this cancer are over 40 years of age, although younger 
patients with regular exposure to risk factors associated with oral cancer can also present 
with potentially malignant and malignant oral mucosal lesions.1, 3 Known aetiological risk 
factors include tobacco, betel quid, alcohol, and micronutrient deficiency.1, 3, 4 Avoidance of 
these will reduce the probability of normal cells transforming to malignant cells.4 In some 
cases though – namely, oral cancer in women under 45 years of age, tobacco use and alcohol 
consumption do not appear to play a role.1 Instead, recent studies have suggested human 
papillomavirus (HPV) as a possible causative factor in cancers of the base of tongue, tonsils 
and oropharynx.1, 2, 4  
Early detection of potentially malignant oral lesions (PMOLs) is important for improving 
the probability of complete recovery, since the stage of malignancy at the time of diagnosis 
influences morbidity and mortality.1, 3, 5, 6 In most countries, the five-year survival rate is 
about 50% but can be as low as 15% if the cancer has spread to the lymphatic circulation.1, 6 
Unfortunately, more than 60% of patients present with stage III and IV oral cancer.5 It is 
therefore important for all clinicians to recognize potentially malignant changes in oral 
mucosa and early-stage oral cancer in a visual and tactile examination, even though PMOLs 
may not become malignant.1 In fact, only a small percentage of dysplastic lesions, and even 
fewer non-dysplastic lesions, undergo malignant transformation.1, 3 PMOLs can be 
asymptomatic patches of white, red or speckled red-white,1-3 with sharp or distinct borders 
and surface irregularity.2 When these patches cannot clinically be characterised as any other 
condition, they are termed leukoplakia, erythroplakia and erythro-leukoplakia (speckled 
erythroplakia) respectively.1 The most common PMOL is leukoplakia, although 
erythroplakia and erythro-leukoplakia have a higher likelihood of becoming malignant.1-3 If 
undetected, they may turn into invasive cancer by growing or enlarging, causing tissue 
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destruction, induration, and fixation to deeper structures.2, 3 Pain, dysesthesia, paraesthesia, 
loss of function, dysphagia, dysarthria, odynophagia, tooth mobility and cervical 
lymphadenopathy may also be present in invasive oral cancer.2, 3 Hence, it is clearly 
important to detect potentially malignant oral mucosal lesions early. 
Although many new technologies exist for helping clinicians detect lesions at an earlier stage, 
delay in detection still occurs, and this can be both patient and practitioner mediated, with 
patient delay contributing to the greatest proportion of total delay time. By targeting this 
delay, there is potential to detect lesions at an earlier stage, thus improving survival rates.  
Screening programs serve to detect disease and allow for early intervention. In the case of oral 
cancer, early recognition and subsequent treatment of potentially malignant and malignant 
lesions is the key to improving 5 year survival rates.
7
 Despite the fact that early detection and 
treatment increase survival rates and decrease morbidity, over the past few decades the 5-year 
survival rate has not significantly improved.
8
 Despite the oral cavity being accessible to visual 
inspection, most cancers are diagnosed at a late stage of disease which can negatively impact 
prognosis.9-12 Not only is survival compromised, but there is greater possibility for 
disfigurement and functional disturbances that can adversely affect the patient’s quality of life 
post treatment.13, 14 Diagnosis of oral cancer at an early asymptomatic stage is rare, with most 
patients seeking help only after the onset of symptoms.9 
Delay in detection can be attributed to both the patient and practitioner and the key to 
improving survival rates is reduction of this delay. Patient delay is defined as the time 
between the patient’s recognition of symptoms and their first consultation with a healthcare 
provider.8 It is commonly recognized that patient delay constitutes the largest proportion of 
total delay time, although the amount varies between studies.8, 10, 12, 15-20 Reasons for patient 
delay have been hypothesized and explored, however findings have been inconsistent. This 
may be in part due to differences in the population under study, study design or recall bias. 
Professional delay has been described as the time between a patient’s initial consultation 
with a healthcare worker to the time of definitive diagnosis.8 It has been proposed that only 
about 1 in every 63,000 patient visits will yield a positive tumour screen. This inherent rarity 
of detection may place the practitioner at a decreased vigil.21 Although we rely partially on 
the patient to notice and present with symptoms, there is a professional and legal 
expectation on the dental practitioner to be able to identify a lesion and appropriately 
refer.21 It is expected of general dental practitioners that upon patient presentation, oral 
cancer screening will occur.22, 23 
Current literature has attempted to identify reasons for delay, however these appear to be 
diverse and dependent on the context of the study. Patient socioeconomic factors such as 
age or gender are usually not found to relate to duration of delay; neither are lesion factors 
such as size or location. Self medication has often been associated with longer delay. So 
while the knowledge base of this area of research is growing, more work is clearly needed. 
Further qualitative studies are required to explore factors which influence both patient and 
practitioner behaviors surrounding oral cancer detection and diagnosis. Qualitative 
methods are capable of eliciting contextually rich information to provide greater insights 
into factors associated with delay. Screening for oral lesions is not occurring consistently, 
with practitioners often citing a lack of time, financial incentives or training as barriers. 
Dental and medical practitioners are often unaware of where their duty lies in terms of 
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screening for oral cancer, however both disciplines express the need for education on both 
oral cancer detection and referral pathways. Further research is required in this field to 
inform effective interventions. 
2. Screening 
Oral cancer screening is ‘the process by which a practitioner evaluates an asymptomatic 
patient to determine if he or she is likely or unlikely to have a potentially-malignant or 
malignant lesion’.2 This definition implies more than a visual and tactile examination of the 
oral mucosa and includes assessment of the patient’s risk profile - at a minimum a 
consideration of their age, tobacco and alcohol use. The aim of screening is to enhance the 
early detection of oral cancer and pre-cancer, and thereby enhance patient survival and 
outcomes. Due to the relatively low prevalence of oral cancer, population based screening is 
not currently justified.24 Opportunistic screening (conducting an oral mucosal examination 
when the patient presents for periodic examination or other treatment), or targeting of 
groups known to be at higher risk for oral cancer is likely to be more cost-effective.25 The 
profile of a high risk individual is that of an older male with a heavy use of tobacco and 
alcohol, poor diet and of low socioeconomic status.9, 26 Emerging knowledge of the role of 
human papillomavirus (HPV) in the pathogenesis of oral cancer however is challenging the 
relevance of this profile. HPV positive oral cancer is associated with younger age and does 
not appear to be linked with gender, alcohol or tobacco use.27, 28 
While the purpose of screening is to detect oral lesions, it also provides an excellent 
opportunity for the practitioner to engage the patient in a discussion about oral cancer. This 
serves to raise patient awareness about oral cancer generally, its risk factors and the 
importance of the screening examination that has just been performed. Patients may also 
examine themselves for early signs of oral cancer, however evidence for the usefulness of 
this approach is currently limited.29, 30 The effectiveness of any screening program will be 
influenced by a number of factors. These factors include those relating to the patient, the 
practitioner, the availability and demonstrated efficacy of diagnostic aids, and those factors 
relating to the health system. These will be discussed in detail in the following sections. 
3. Patient factors 
Patient delay is defined as the time it takes for patients to seek help following self discovery 
of symptoms.8 This term is widely accepted however it should be interpreted cautiously so 
as not to infer blame on the part of the patient. The mean patient delay varies between 
studies, with anywhere from 11 weeks to 6 months cited.12, 17 Mean patient delay can be 
affected by large outliers in studies and for this reason it is useful to also include median 
delay, however not all studies report both.31 Some studies collect data on a categorical basis, 
reporting the percentage of patients that present within a given time frame. It is difficult to 
define what excessive patient delay is, however a reduction in mean and median values 
would improve survival rates. 
3.1 Public awareness of oral cancer 
The public know little about the clinical presentation of oral cancer, although most are 
aware it is usually detected in late stages of disease.32 Most people are able to identify 
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tobacco and previous experience of oral cancer as risk factors, but less people are aware of 
other risk factors such as alcohol, older age and poor diet.32 Flyers and brochures in dental 
clinics may increase awareness of oral cancer. They may not only prompt patients to request 
a mucosal screening, but also motivate them to be more aware of self screening 
opportunities.33 Leaflets have been shown to render patients more open to mucosal 
screening, with educational self screening pamphlets also resulting in high compliance.33, 34 
Not all practices however will promote awareness of oral cancer, as they believe it will 
create patient anxiety.6, 35 This worry was unfounded in a study of dental professionals who 
attempted to integrate screening into their practices, finding patients had a positive 
disposition towards screening for oral cancer.35 Although most patients were aware of oral 
cancer, some reported being totally unaware of the potential for it to occur.16 Most patients 
who were aware of oral cancer had minimal knowledge.16 Lack of awareness and 
knowledge of oral cancer has been reported to increase patient delay, thus making 
information available to patients may be a vital part in improving survival rates.21 Although 
surgeries can make pamphlets available in the waiting room, it has been shown in 
numerous studies that those patients most at risk of developing oral cancer do not regularly 
attend a dentist.21, 36-38 Television has the potential to reach a wider audience and educate 
about the importance of self screening and prompt presentation to a practitioner. Following 
an oral cancer campaign in Scotland, two thirds of those surveyed remembered hearing 
about oral cancer six months prior.39 The majority of those patients saw it on television.39 
Around half of the patients felt encouraged to seek help because of the campaign.39 In 
another study, several patients diagnosed with oral cancer remember having seen a 
television commercial, with two patients presenting to a health care professional as a result 
of these commercials.16 Although television has the potential to reach a wide audience, oral 
cancer has a relatively low prevalence. For this reason it has been suggested a more cost 
effective mechanism is to target those most at risk of the condition.40 
3.2 Self medication contributing to delay 
Scott et al. performed a systematic literature review of articles published between 1975 and 
2005 to identify known factors associated with patient delay.20 The majority of factors 
investigated in studies reviewed were not shown to be related to the duration of patient 
delay. This may be because studies regarding patient delay are few in number and not all 
are considered rigorous in terms of study design.20 In Thailand, it was reported that patients 
who had used traditional herbal medicine had a longer duration of delay.20, 41 Self 
medication being associated with longer duration of patient delay has since been 
demonstrated in other studies. Patients may attempt to treat symptoms with over the 
counter products, with some seeking advice from pharmacists who commonly advise gels, 
creams or mouthrinses.16, 42 These patients then wait to see whether their oral condition 
resolves following self medication, increasing duration of delay.18 This highlights the 
importance of the pharmacist’s awareness of oral cancer as they may be an initial point of 
call for a patient developing oral symptoms.37, 42 One study showed that after pharmacies 
were given an educational package on oral cancer, more staff advised a mystery shopper 
querying a 4 week old non healing ulcer to present to a healthcare practitioner.43 Although 
the shopper could be advised to visit either their doctor or dentist, most staff advised the 
shopper to visit a doctor.43 Following the intervention only 45% of staff advised help seeking 
behavior, however this was higher than prior to the intervention.43 A limitation of this study 
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was that only one staff member was approached at each pharmacy, and this may not have 
been representative of the overall impact of the educational material provided. Not only are 
patients self medicating symptoms before diagnosis, one study has demonstrated that 
patients often trial alternative therapies before undergoing conventional cancer treatment.44  
3.3 Socio demographic factors contributing to delay 
Studies consistently report no correlation between age and delay, however, whether other 
factors such as gender, financial status, location or size of lesion play a role in patient delay has 
not yet been substantiated, with studies often generating conflicting results.8, 15-17, 41, 45-50 Gender 
is not usually demonstrated to influence duration of delay8, 15-17, 41, 47-49, 51. Only one study 
contradicted this, with women taking longer to present to a practitioner following self 
discovery of symptoms.12 However in this study there was a male/female ratio of 5.4/1, with 
only a small number of females.12 Two studies noted unmarried patients exhibit longer delay, 
both suggesting this is because married patients have more support.17, 52 As other studies did 
not show marital status influenced delay, the differences may be a result of cultural factors. 
Two studies found longer delay in non smokers.17, 45 Patients who do not smoke may feel that 
since they are at lesser risk of developing oral cancer, their lesion is not of concern.17 This being 
said, patients who smoke and drink alcohol are more likely to present with concurrent illness 
and they often have poorer prognosis partly due to increased delay.53 Heavy drinkers have 
been shown to display an increased duration of delay, and in the same study only light 
smokers demonstrated excessive delay.54 Difficulty obtaining access to a practitioner is often 
shown to influence delay.19, 55 A study comparing the waiting time for patients to see a dentist 
established that those with potentially malignant lesions (ulceration) were seen much faster 
than those requesting prosthetic treatment, showing dental surgeries will prioritise cases.56 
Eleven percent of appointments in this study were made because of symptoms similar to oral 
cancer. Unfortunately however a comparison of waiting times for other symptoms such as 
prolonged pain or numbness was not incorporated.57 Patients afflicted with oral cancer are 
often of low socioeconomic background and financial barriers may play an important role in 
patient delay.55 Practitioners agreed that patients of low socioeconomic background exhibited 
greater delay.58 This is exemplified by the high patient delay experienced in the USA 
compared to Canada.10 The USA has a healthcare system whereby individuals pay for their 
own health expenses, whereas in Canada some healthcare is provided by the government. One 
study did however report that most individuals in the USA diagnosed with oral cancer had 
health insurance coverage, and those that had no coverage did not exhibit excessive delay.46 A 
study performed in the UK reported that an oral cancer patient waited to see a free NHS 
dentist rather than be seen immediately by a private dentist, for which a fee would be charged. 
8 Only three out of 44 patients interviewed in England identified costs of a dental check up to 
be a large barrier.42 Financial barriers are dependent on the health care system utilised in the 
country where the research is performed, further complicating study comparisons.  
3.4 Lesion factors contributing to delay 
Most studies have found tumour factors such as site, symptoms, size and stage did not have 
an association with duration of delay.8, 18, 41, 47 One study indicated that patients with oral 
cancer located in more commonly found sites such as the tongue, floor of mouth and 
retromolar pads presented faster than those with cancer located in uncommon sites such as 
on the hard palate and gingivae.12 However the small number of individuals with cancer in 
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uncommon sites in this study means that the results should be interpreted with caution.12 
Another study also showed that lesion site was associated with delay, but again a small 
sample size of uncommon cancer sites meant they were also unable to draw strong 
conclusions.15 Those with cancer in more visible sites such as the lip or tongue have been 
shown to be diagnosed at earlier stages than others.49 A lesion’s maximal diameter was 
shown to be inversely proportional to delay by one study.15 The patient’s interpretation of 
symptoms has commonly been shown to influence duration of delay. The most common 
oral symptoms noticed by a patient are a non healing ulcer or sore, persistent lumps or 
swellings, sore tongue or mouth and sore throat, abscess or boil.42, 49 Patients sometimes 
attribute these symptoms to an infection, dental problem or problem with a prosthesis.51 
Those that believe their lesion to be innocuous will often wait longer to be seen by a health 
care practitioner.8, 18, 42, 51, 59 Some patients are aware there is a chance their symptoms are 
cancerous, but do not believe they are.59 This highlights the need for both awareness of oral 
cancer presentation and the understanding that anyone may be afflicted. One study 
revealed patients also require guidance on how to interpret oral symptoms.40 Of patients 
diagnosed with oral cancer, most can retrospectively pinpoint symptoms attributable to 
cancer and the majority of patients diagnosed with oral cancer report presenting as a result 
of their symptoms.16, 46 This being said, symptom recognition is not a reliable method of 
detecting tumours at an early stage since about 25% of oral cancers remain silent until they 
reach an advanced size.21 Although tumours may not necessarily be detected at an early 
stage, attribution of symptoms to cancer can at least lead to earlier detection. 
3.5 Barriers and triggers to help seeking 
Understanding the barriers and triggers to help seeking is crucial to institute effective 
mechanisms to decrease patient delay. Patient delay should not be influenced by whether 
the patient actually has a malignant lesion, since both benign and malignant lesions can 
exhibit similar symptoms. Despite this, most studies only include patients with a diagnosis 
of oral cancer. A more recent study took this into account and included patients who had 
potentially malignant lesions.19 As was the case with patients diagnosed with oral cancer, 
patients delayed seeking help as they believed their symptoms were minor and some 
attempted self care prior to seeking help.19 One study hypothesized that patients who had 
previously experienced benign lesions may have longer delay time, since they are less 
inclined to believe their condition needs attention.15 Some patients had a negative attitude 
towards dental practitioners due to a previous negative experience or apprehension, with 
others not wanting to waste practitioners’ time.19, 51 Only about half of the patients 
interviewed in the USA had a regular dentist.46 Often patients were found to have 
competing responsibilities or priorities such as work commitments or comorbidities.19 Most 
previous studies have only looked at the barriers to help seeking. In order to institute 
effective public awareness however, triggers should also be identified. One study which 
queried patients about the triggers, found patients presented following either a change in 
symptoms, if they had another reason to visit a practitioner, had a fear of worsening 
symptoms, excessive worry, dislike of symptoms or were advised by significant others.19 
Attribution of symptoms to something sinister will not always inspire help seeking 
behaviour, with a fear of diagnosis sometimes leading to delay.55 Another study also 
investigated triggers to presentation, finding the dominant triggers to be anxiety and worry, 
need to resolve uncertainty, avoidance of problems getting worse and being advised by 
others to seek help.42 Being advised by others to seek help has been shown to trigger help 
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seeking behavior in subsequent studies, as well as receipt of new information from sources 
such as media or medical literature.59 Development of a neck mass usually inspires a patient 
to visit a healthcare practitioner, however by this stage it is well advanced.51 Most studies 
are conducted retrospectively, meaning they are subject to significant recall bias. Gao et al. 
instituted a system whereby family members were requested to confirm descriptions in 
order to decrease recall bias.15 It was however found by Rogers et al. that the majority of 
patients will wait up to a month before telling anyone about their symptoms.42 It is not 
apparent whether family members will be subject to the same recall bias, or simply tend to 
agree with the patient. 
4. Practitioner factors 
As with patient delay, a wide variance of mean and median professional delay time has 
been cited. This can be attributed to differing definitions of delay, recall bias or incomplete 
records. Although professional delay does not tend to contribute greatly to total delay, it is 
arguably the easiest part of delay to target. Professional delay has been proposed to occur as 
a result of lack of rigour in screening, lack of confidence in detection, low prevalence rates, 
inadequate knowledge and lack of incentives for screening. 
4.1 Mucosal examination 
A dentist’s attitude to screening is an important factor in detecting early malignancy, as 
unless patients present with a complaint there is complete reliance on the dentist to identify 
mucosal lesions.60, 61 It has been shown that patients who develop an oral cancer and who 
regularly attend a dentist are more likely to have their cancer diagnosed in its early stages.46 
Often, asymptomatic lesions are discovered incidentally during dental examination.47, 62, 63 
However, even following a routine dental examination malignant lesions are sometimes 
missed. This was demonstrated in a study where oral and maxillofacial surgeons detected 
oral cancer in patients referred for extraction of teeth.47 The majority of dentists claim to 
perform mucosal screening for every patient, and in some cases they target screening to 
individuals over the age of 40.14, 64 Of dentists working in nursing homes in Ohio, 83% 
reported performing mucosal exams for each patient, although only half actually identified 
increasing age as a risk factor for oral cancer.65 Screening practices are found to be 
inconsistent between studies; only a third of dentists in Germany reported performing 
routine oral cancer examinations.66 In the same study, only 66% of dentists questioned felt 
adequately trained to examine patients for oral cancer, despite the majority agreeing that 
dentists are qualified to perform these examinations.66 In this study, questionnaires were 
sent out with a dental association journal and there was a response rate of only 14%, 
resulting in biased data, so the real picture is likely to be even worse.66 Similar results were 
found in a separate study when questionnaires were sent to dental and medical 
professionals.67 Although some practitioners cited a lack of time as a barrier to screening, the 
reality is that it takes less than 2 minutes to perform a thorough head and neck exam.35, 38 
Lack of financial incentives to perform mucosal screening may therefore be impeding on 
motivation to do so.35 Almost all dentists surveyed in a study in Ohio felt oral cancer 
screening should be a separate reimbursable procedure, with all agreeing mucosal 
examinations should occur for all patients over 40 annually.65 Lack of rigour regarding 
screening may be the result of the relatively low incidence of oral cancer; the average dentist 
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only encounters about 2 tumour cases during a lifetime.21, 61 Clinicians should however be 
performing mucosal examinations not only to pick up cancer, but also other lesions, 
including potentially malignant lesions. What motivates a clinician to undertake a mucosal 
exam is yet to be determined, however if practitioners are only undertaking a mucosal exam 
to detect oral cancer the low prevalence rates may indeed play a role. 
4.2 Risk assessment 
Alcohol and smoking are prominent risk factors for of oral cancer.7 Some practitioners will 
take this into account and perform a more thorough mucosal exam for smokers while others 
do not consider this a factor influencing their screening behaviour.61, 68 One study 
demonstrated that dentists will often take into account risk factors when deciding whether to 
refer.22 Dentists are in a position to provide smoking cessation advice. It has been shown 
however that some dentists don’t believe there is any benefit providing this advice due to lack 
of financial incentives, a belief that people do not want the advice or the belief that patients do 
not want to quit.6, 37, 69 The belief that patients don’t want smoking cessation advice has been 
contradicted since, with about half the dental patients surveyed suggesting they would try to 
quit if advice was offered.69 Almost two thirds of dentists questioned in Germany agreed 
dentists should be trained to provide smoking cessation, but only about a quarter felt they 
were able to provide advice.66 Although a number of dentists claimed to provide smoking 
cessation advice, only a small number follow up with the patient and help them to quit.64 The 
number of dentists requesting information about and providing advice on a patient’s drinking 
habits has consistently been even lower.37, 64, 66 This may be a result of less awareness of the 
role of alcohol in oral cancer.37 About two thirds of dentists surveyed in Germany believed 
dentists should be trained to provide smoking cessation advice, and more than 50% felt 
training in alcohol cessation was important.66 It has been suggested that compulsory 
continuing education should be implemented to educate practitioners about the effects of 
tobacco and alcohol on the oral mucosa and how to provide cessation advice.64 Although 
practitioners may be aware of the risk that alcohol and smoking pose to the patient, there is 
still a lack of readiness to provide support to patients in modifying their risk behaviors. 
Patients diagnosed with oral cancer don’t always link their smoking habits as a causative 
factor, highlighting the importance of public awareness of risk factors.16 Targeting high risk 
groups for screening has been proposed as a feasible screening plan.21 Practitioners involved 
could be trained to assist patients with reducing their risk from lifestyle factors such as tobacco 
and alcohol. They would therefore not only detect lesions earlier but also work with their 
patients to help them reduce their risk. Diagnostic delay has been associated with increased co-
morbidities, which is concerning as over 25% of head and neck cancer patients also have 
illness in more than one body part.53 These co-morbidities are often tobacco associated.53 
4.3 Practitioner knowledge of oral cancer 
It has been shown in some studies that practitioners lacked confidence in detecting cancer; 
however this has been contradicted in other studies.14, 61 Dentists are often looking for cancer 
as opposed to potentially malignant lesions. Changing this philosophy is important in 
ensuring lesions are identified at an early stage where treatment is less radical.61 Dentists 
should be able to determine whether a lesion has malignant potential or is already 
malignant, with non homogenous lesions being referred straight away.7 Non homogenous 
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leukoplakia is often shown to have a marked increase in malignant change when compared 
with homogeneous leukoplakia.7, 70 Erythroplakia exhibits higher malignant potential, with 
about half these lesions showing invasive carcinoma.7 Alarmingly, health care providers 
surveyed in Scotland were more concerned about leukoplakia than erythroplakia.37 This 
study included general medical practitioners as well as general dental practitioners with no 
distinction between groups in terms of oral cancer knowledge. Another study suggested 
that dentists do give due concern to erythroplakia.61 A study comparing oral cancer 
knowledge between doctors and dentists found that dentists could identify more risk factors 
and oral changes associated with oral cancer.68 It was shown that dentists are more 
confident in detecting oral cancer than doctors, despite most patients presenting to their 
doctor regarding oral lesions.11, 21, 37, 42, 47 Patients may present to a doctor rather than a 
dentist because they do not view their oral lesion as a problem with their dentition or 
dentures, thus there is a need for the public to be made aware that it is appropriate to go to 
their dentist if they become aware of a mucosal lesion.47 Doctors perceive lack of training 
and time to be barriers to oral cancer screening, similar to the dentist’s disposition.37 Doctors 
could be advised that if there is an oral condition they are unsure of, patients can be advised 
to seek the opinion of a dentist. It could be argued that this referral could contribute to 
delay, however Macpherson et al. found most doctors will refer if a lesion persists for 4-5 
weeks compared to most dentists who wait only the recommended 2 weeks.37 Although 
Jovanovic et al. found no significant difference in delay between doctors and dentists, their 
study analysed the records of 41 patients whereas Macpherson et al. sent questionnaires to 
357 doctors and 331 dentists.37, 47 Using questionnaires to record behavior introduces bias in 
itself, making interpretation difficult. 
4.4 Need for continuing education 
When practitioners are interviewed, they often exhibit the belief that there should be 
compulsory continuing education courses in oral cancer.35, 58 Participants in one study wanted 
to know more about referral pathways, biopsy procedure and guidelines for screening.35 
Courses have been shown to be effective in promoting screening methods, with practitioners 
reporting better screening habits following attendance.35, 58 A lack of confidence in detection 
has been made apparent as some dentists did not feel that they should deal with diseases such 
as cancer as they are “not medical doctors”.35 This lack of confidence also extends to doctors, 
as both doctors and dentists felt that they had inadequate training and were not confident in 
detecting oral lesions.37 If that is the case, further compulsory continuing education courses on 
oral cancer could help to shift this belief and make practitioners more aware of their 
responsibility. Practitioners who have undertaken more recent continuing education courses 
in oral cancer have had greater knowledge in the area.14 Despite the benefit of such courses, 
about one third of dentists from a Western US multistate dental practice group reported 
having never attended a continuing education course on oral cancer.14 An association has been 
demonstrated between knowledge of risk factors and diagnosis, and number of lesions 
referred or biopsied by a practitioner.71 
4.5 Referral and patient mediated professional delay 
Some studies have found dentists will wait 2 weeks to review a lesion prior to referral. This 
is recommended since oral cancer can mimic traumatic lesions which resolve in 2 weeks.6, 37, 
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50 A difficulty in implementing the two week rule is that patients may delay in presentation 
for the second appointment, for reasons similar to initial delay.72 In some cases, patients can 
also delay in effecting a referral.58, 72 For this reason practitioners should convey urgency to 
the patient if a suspicious lesion is referred.50 Not only should practitioners convey urgency 
to the patient, but also to the specialist, since mentioning malignancy or possibility of a 
tumour in the referral letter, or accompanying a referral letter with a phone call can 
categorise a referral as urgent.50 Specialists will prioritise a patient if malignancy is 
suspected. Dentists have been shown to display difficulty in conveying their suspicions in 
referral letters, especially when compared to their medical counterparts.73 Practitioners 
should also follow up referred patients to ensure they are utilising their referral, effectively 
decreasing this proportion of professional delay.72 Patient anxiety has been shown to modify 
the decision to refer.6, 61 Although it is important to allay the concerns of an anxious patient, 
a suspicious lesion should be referred regardless of whether the patient is concerned. Cues 
for frank malignancy are more likely to prompt a referral when compared with 
premalignancy and it has been demonstrated in numerous studies that if a practitioner is in 
doubt, they will refer. 22, 61 Again, greater emphasis needs to be placed on the detection of 
potentially malignant and premalignant lesions if a decrease in delay is sought. 
Not only does referral involve the practitioner identifying and referring a patient for 
examination, there is a distinct need to communicate to the patient why they are being 
referred. A part of professional delay that is difficult to control for in studies is patient 
mediated professional delay, that is when patients do not attend a specialist appointment for a 
prolonged period of time following referral.10 The need for a patient to promptly attend a 
specialist appointment should be communicated to the patient without causing undue 
distress. Rogers et al. found 1 in 6 patients were not satisfied with advice received upon their 
first medical consultation, however whether patients were dissatisfied with either advice given 
from a doctor or dentist was not represented and the reasons they weren’t happy was also not 
explored.42 The practitioner should be able gauge the patient’s emotional and social well being 
and deliver medical information that the patient is able to comprehend.36 Upon issuing a 
referral, practitioners will often tell the patient they have seen something suspicious and 
would like a second opinion.6 Dentists worry about using language to avoid anxiety, tending 
to refrain from using words associated with malignancy and some believe this helps calm the 
patient.6 Following questioning from the patient regarding possibility of oral cancer, dentists 
tend to say they do not think the lesion is malignant.6 Although this may help decrease patient 
anxiety, there is also a need to ensure that the patient also sees the issue of obtaining a 
definitive diagnosis as urgent. Both medical and dental practitioners believe more training in 
detection and referral pathways are necessary.37 
4.6 Delays between diagnosis and treatment 
Once a diagnosis of oral cancer has been made, delay can occur in obtaining treatment for 
these patients. Not only does this delay cause stress to the patient, tumour size may increase 
during this time period.74 Alarmingly, a study in Denmark showed the amount of delay 
increased from 1992 to 2002. This was attributed to a shortage of radiotherapy capacity.75 
They also observed that more imaging procedures were carried out, but could not prove a 
cause and effect relationship.75 In one study factors such as ethnicity, primary site and 
insurance correlated with delay between diagnosis and treatment.76 It has been suggested 
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that longer planning time is needed for complex cases, thus some delay in this instance 
appears warranted.76 
5. Health system factors 
The structure and organisation of a country’s health system is a critically important yet 
poorly recognised factor influencing the early detection of oral cancer and pre-cancer. It can 
contribute to both patient and professional delay. Low socioeconomic status has been 
previously discussed in this chapter as a barrier to accessing health care for the symptoms of 
oral cancer. Financial barriers to health care depend on the funding model of the health 
system. If health care is funded by the government then theoretically this barrier is removed. 
However, real access to public health care also depends on the available resources. 
Inadequately resourced public health care results in waiting lists. This forces patients to seek 
care in the private sector, or to neglect health care. In addition, health systems that ensure 
culturally safe practice enhance access for groups at high risk, Indigenous and recent 
immigrant populations.77 Whether the health system values and supports prevention and 
early detection will influence practitioner behaviour in performing a thorough screen 
including a risk assessment and providing support for patients in modifying their health 
behaviours. If the practitioner is reimbursed for these activities or in the case of the public 
sector, if this contributes to productivity targets, then these behaviours are likely to be 
valued by the patient and occur more frequently.  
Health systems globally are stretched ever further dealing with the challenges of an ageing 
population and the increased burden of complex chronic diseases. Dental health systems are 
often prioritised lower than general health systems and so public funding for oral health 
care may suffer a significant shortfall. Oral cancer, similarly to other oral disease, is almost 
entirely preventable. If it can be detected early, the outcomes are substantially better. 
Putting aside the gains in human health and quality of life, from a purely cost perspective, it 
makes sense to invest in programs which focus on the prevention and early detection of all 
oral diseases, including oral cancer. The health care team paradigm is now well accepted as 
a necessity for providing optimal patient care. In a number of countries, including Australia 
and New Zealand, oral health therapists are tertiary trained practitioners who work in the 
dental team. They have expertise in recognition of oral abnormalities, risk assessment and 
health promotion.78 Novel models of care, in which oral health therapists are used to screen, 
risk assess, provide support for health behaviour modification and refer for treatments 
outside their scope of practice, are currently being trialled. Continuing education programs, 
and the establishment of clear clinical guidelines and criteria for referral79 are agreed to be 
necessary to support primary care clinicians in confidently and effectively performing oral 
cancer screening for their patients. 
6. Diagnostic aids 
The quest for reduction in professional delay of detection, and a desire to improve early 
detection of oral cancer has driven the development of diagnostic aids designed to improve 
visualisation of malignant and potentially malignant oral lesions.  Methods for visualising 
and detecting PMOLs include conventional oral examination (COE), vital tissue staining, 
light based detection systems which rely on tissue reflectance (ViziLite, Microlux/DL), and 
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autofluorescence (VELscope, Identafi). Several key issues are considered when assessing a 
particular diagnostic aid.  These include the effectiveness of the visualisation method in 
detecting oral cancer and precancer; whether or not the method can distinguish 
premalignant or malignant lesions from other benign conditions; and if an accepted “gold 
standard” comparison such as scalpel biopsy and histopathological assessment was used in 
assessing the efficacy of the diagnostic aid.  Where possible, sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) are used to determine the 
effectiveness and accuracy of each aid.  Sensitivity is the proportion of people who have the 
disease and test positive, while specificity refers to the proportion of people who do not 
have the disease and test negative.  PPV is the proportion of people with positive test results 
who have the disease, whereas NPV is the proportion of people with negative results and do 
not have the disease. 
6.1 Conventional oral examination 
Conventional oral examination under normal incandescent or halogen light illumination is 
the standard method for screening for oral cancer.5 It typically involves visual inspection of 
the oral cavity and palpation of the lymph nodes for clinical signs of abnormalities such as 
changes in colour, texture, ulceration, persistent swelling and enlarged lymph nodes.1  
Several studies have reported relatively high sensitivity and specificity values for COE.  In a 
prospective study involving two oral cancer screening programs, over 2,300 people 
underwent a thorough oral examination by a dentist.80 An oral medicine specialist then 
examined participants to give a definitive ‘true’ clinical diagnosis, thus providing a “soft” 
gold standard.  The combined sensitivity and specificity of these two screening programs 
was 0.74 and 0.99 respectively,80 which is consistent with sensitivity and specificity values of 
other screening programs.81-83 The results from this study, along with six other prospective 
studies with calculated sensitivity and specificity, were included in a meta-analysis by 
Downer et al.84 These studies reported a range of sensitivity and specificity values, from 0.60 
to 0.97 and 0.74 to 0.99 respectively.  When pooled together, the overall sensitivity for COE 
was 0.848 while the overall specificity was 0.965.84  This indicates that COE has relatively 
few false negatives, and even less false positives.  However, the ability of a clinician to 
screen for potentially malignant and malignant lesions will vary, depending on their 
knowledge and clinical judgement.  Nonetheless, Downer et al.’s heterogeneity analysis of 
the eight studies found that dentists and specifically trained basic health workers can screen 
with similar degrees of accuracy.84 
Despite the relatively high sensitivity and specificity, there is still some controversy about 
the use of COE as clinicians often cannot purely use this method to discriminate progressive 
from non-progressive lesions, and benign from malignant lesions.85 For definitive diagnosis, 
an incisional biopsy with histopathological analysis is required.1, 3  Furthermore, not all 
early lesions are easily seen under a dental operating light.2, 5, 85, 86 In a pilot study by 
Thomson, 26 untreated patients with either a PMOL or unilateral OSCC had a biopsy of 
clinically normal-looking mucosa taken from the corresponding, contralateral anatomical 
site.87 After histological assessment, 6 (23%) samples had reactive changes, 7 (27%) had some 
form of dysplasia (mild, moderate or severe), 1 (0.04%) had carcinoma in situ (CIS) and 1 
(0.04%) had microinvasive squamous cell carcinoma.87 Sites with a high proliferation rate 
such as the ventral tongue and floor of mouth, and were exposed to carcinogens, were also 
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found to be more susceptible to dysplastic changes.87  It is therefore particularly important 
to identify high-risk patients so that an even higher level of suspicion is maintained when 
examining these patients, especially since a randomised controlled trial (RCT) reported a 
significant decrease in mortality in males who used alcohol or tobacco, or both, when they 
were screened for oral cancer.88 However, a recent Cochrane review assessed this RCT and 
cautioned the interpretation of this statement, as the study had several methodological 
problems which may have introduced bias.24 Furthermore, since this study was conducted 
in India where the prevalence of oral cancer is higher, results from this study may not be 
applicable to low-prevalence populations.24 More RCTs are required as there currently is 
insufficient evidence to support oral cancer screening with COE in the general population.  
Nonetheless, it is clear that COE alone is not perfect.  Therefore, the use of an adjunctive 
technique that has high specificity and sensitivity for highlighting PMOLs and OSCC should 
aid a clinician in detecting and diagnosing these lesions at an early stage, and consequently 
improve prognosis.85 
6.2 Vital tissue staining 
Tolonium chloride, more commonly known as toluidine blue (TB), is an acidophilic 
metachromatic dye of the thiazine group that preferentially stains nucleic acids and 
abnormal tissues.5, 89  The increased nuclear density and the loss of intracellular adherence 
in dysplastic and malignant tissues allows TB dye to penetrate through the epithelium and 
be retained in these tissues, thereby staining these areas of abnormality blue.89, 90 Although 
TB has primarily been marketed as an adjunct for detecting potentially malignant and 
malignant oral lesions not identified by COE, it has also been recommended for determining 
the risk of potentially malignant oral lesions progressing to cancer, monitoring suspicious 
lesions, determining the optimal biopsy site, assessing the extent and margins of potentially 
malignant and malignant oral lesions, and for assessing the outcome after treatment for 
dysplasia and cancer in follow-up appointments.90, 91 Until recently, TB was commercially 
available as kits under the trade names ‘OraScan’ (Germiphene), ‘OraScreen’ (Stafford-
Miller Ltd.) and ‘OraTest’ (Zila Pharmaceuticals).  However, TB is now available as part of 
ViziLite Plus under the name, TBlue630 (Zila Tolonium Chloride) Oral Lesion Marking 
System, and may be used at the discretion of the clinician for demarcating any lesion that 
requires further study or biopsy.92  
Whilst there is extensive literature on TB, many only provided background information, 
expert opinion and/or described a technique but did not provide additional data.90 An early 
meta-analysis by Rosenberg et al. of 12 studies conducted between 1964 and 1984 reported 
93.5 to 97.8% sensitivity and 73.3 to 92.9% specificity for the detection of oral cancers.93 A 
later systematic review by Grey et al. of 14 studies conducted between 1970 to 1999, half of 
which were also included in Rosenberg et al.’s paper, reported sensitivity varying from 40 to 
100% and specificity from 31 to 92%.90  Another recent systematic review of adjuncts to oral 
examination assessed 15 studies from 1967 to 2005.94  In this review, sensitivity and 
specificity of TB as a diagnostic adjunct ranged from 38 to 98% (median 85%) and 9 to 93% 
(median 67%) respectively.  PPV varied from 33 to 93% (median 85%) and NPV from 22 to 
92% (median 83%).94 Although there are discrepancies in the sensitivity and specificity 
ranges due to the different inclusion and exclusion criteria of these reviews, the median 
values suggest that TB has high sensitivity but relatively lower specificity.   
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Findings from an observational study of 45 oral mucosal lesions by Allegra et al. are 
consistent with this idea.95  Allegra et al. reported 96.2% sensitivity and 77.2% specificity for 
TB staining, with a PPV of 86.6% and a NPV of 93.3%.  In comparison, sensitivity and 
specificity for clinical examination were 53% and 80% respectively, whereas the PPV was 
84.2% and NPV was 46.1%.  There was a statistically significant difference in both sensitivity 
and NPV between TB and clinical examination.  Therefore, TB was better at identifying 
suspected lesions than COE, and had a very low probability of a positive histological result 
coming from a negatively stained lesion.95  These results are consistent with previous 
studies.96, 97 In contrast, a recently published paper of case series by Cancela-Rodriguez et al. 
reported higher specificity than sensitivity.89 Whilst the sensitivity of 65.5% was lower than 
previous reports, the specificity of 73.3% was consistent with other studies.  The PPV of 
35.2% was also lower, which the authors attributed to the lower prevalence of dysplastic 
and malignant lesions in their study when compared with others, whereas the NPV of 90.6% 
was again consistent with other papers.89 
On the whole, the relatively lower specificity values were a result of relatively high numbers 
of false positive findings.  In several studies, TB stained normal variations of anatomy, and 
benign inflammatory and traumatic lesions due to their increased cell activity.89, 96-100 To 
reduce the number of unnecessary biopsies and to exclude inflammatory and traumatic 
lesions, Mashberg suggested restaining any TB-stained lesion after 10 to 14 days.98  Any 
lesion that still stained after this period should be evaluated for cancer by biopsy,98 as 
OSCC, CIS and high-grade dysplasia retained TB fairly consistently.5, 97, 101 Furthermore, a 
prospective longitudinal study by Zhang et al. reported that lesions – including benign 
lesions with high-risk clinical and molecular characteristics – which stained with TB had an 
increased risk of malignant transformation.101  However, staining of all early-stage 
dysplasias does not always occur,5 probably because these lesions do not have the molecular 
changes associated with OSCC progression.102  Conversely, TB has been shown to stain 
lesions that were undetected by COE.90, 103 
Current literature suggests that the use of TB by trained and experienced practitioners may 
be useful in high-risk patients in a specialist setting, as most TB studies have been 
conducted in specialist clinics on higher-risk patients or patients who already have a known 
lesion.5, 94 With only one published community-based randomised controlled trial (RCT),104 
there is insufficient data to support the use of TB as an adjunct to COE in general practice on 
the general population.  In this RCT, 7,975 participants were randomly allocated to either 
the experimental group (TB) or the control group (placebo dye), and were visually examined 
by experienced dentists who were trained by an oral pathologist to detect oral lesions.  It 
was found that the use of TB did not significantly improve the detection rate of PMOLs; 
however, significantly more oral submucous fibrosis and slightly more leukoplakia were 
detected when TB was used as an adjunct than with visual screening alone.  In addition, 
there was no significant difference between the two groups in reducing the incidence of oral 
cancer after five years.  Further RCTs in the general population with longer follow-up 
periods are needed to confirm these results, particularly since the malignant transformation 
of PMOLs has a long natural history.104 
Problems with experimental design and analysis of results are the main reasons contributing 
to the poor quality of many studies on TB.  Care must be taken when interpreting and 
comparing results as methods and definitions are inconsistent.  Common issues that need to 
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be considered include whether or not a non-pharmaceutical grade (laboratory) TB solution 
or a higher standard, pharmaceutical grade TB solution was used, the method of applying 
TB (rinse versus local swab), if a two rinse procedure was used instead of one rinse to rule 
out inflammatory lesions, and the definition of a positive stain.  Staining intensity is a 
contentious issue, with some studies defining a positive result if there is an intense blue 
stain, while in other studies a positive result is if there is any blue staining.5, 91  Further 
complicating this matter is the inclusion of equivocal results in some studies, and whether 
or not they should be considered as positive or negative in statistical analysis.  Grey et al. 
showed that equivocal results can significantly affect statistical values in individual 
studies,90 which may mean that accuracy results are underestimated.94    Interpretation of TB 
stains can therefore be difficult and its use should be limited to trained and experienced 
clinicians, otherwise there may be more unnecessary biopsies taken and higher numbers of 
false positive and negative results.  
6.3 Tissue reflectance (ViziLite, Microlux/DL)  
There are several screening devices marketed as adjuncts to COE that enhance tissue 
reflectance to aid clinicians to detect PMOLs and OSCCs. These devices include ViziLite 
Plus (Zila Pharmaceuticals, Phoenix, Arizona, USA), Microlux/DL (AdDent, Danbury, CT, 
USA) and Orascoptic DK (Orascoptic, a Kerr Company, Middleton, WI, USA).1, 2, 85, 105  
ViziLite Plus utilises a disposable chemiluminescent light packet to provide diffuse blue-
white light between 490 to 510 nm in wavelength.92, 106 Chemiluminescence occurs when a 
chemical reaction produces light which can vary in intensity, lifetime and colour depending 
on the type of reaction.107  In contrast, Microlux/DL and Orascoptic DK use a diffuse white 
light from a battery-powered light-emitting diode (LED).108  Regardless of the type of light, 
these devices claim to enhance tissue reflectance of oral tissues after the mouth has been 
rinsed with 1% acetic acid for 60 seconds.92, 108, 109  According to the manufacturers, a 
cytoplasmic dehydration agent such as acetic acid can alter the refractile properties of oral 
mucosal abnormalities with atypical non-keratinized squamous epithelium, as these cells 
have an increased nuclear:cytoplasmic ratio.92, 108, 109 Consequently, dysplastic lesions 
become more visible as they appear white (hence termed an ‘acetowhite lesion’) against the 
light blue appearance of normal tissue.85, 92, 105, 108-110  
Several studies have evaluated the efficacy of tissue reflectance as a technique for visualising 
and detecting oral mucosal lesions; however, the number of publications available is still 
quite limited.  The majority of these are on ViziLite, with only one study on Microlux/DL 
and none on Orascoptic DK.5 Although several studies have been published regarding the 
efficacy of ViziLite, there appears to be conflicting results.  In a pilot study involving 150 
patients, a variety of hard and soft oral lesions were examined using ViziLite.110 All benign 
lesions without hyperkeratinisation, hyperparakeratinisation, chronic inflammatory 
infiltrate and/or an altered nuclear:cytoplasmic ratio did not appear acetowhite.  However, 
all lesions with a clinical diagnosis of leukoedema and two out of fourteen frictional 
keratoses were ViziLite positive.  In addition, three leukoplakic lesions appeared 
acetowhite. Two of these, including the one that was not detected by COE, had signs of 
cellular atypia, while the third was later diagnosed as a non-specific ulcer.110  This finding is 
consistent with two other papers that reported positive results with a non-specific ulcer,105 
and four cases of traumatic ulcers.111  These results suggest that ViziLite has fairly high 
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sensitivity but low specificity and PPV,5 and this idea is supported by several studies.105, 107, 
112 In a study by Ram and Siar involving 40 patients with a PMOL, primary squamous cell 
carcinoma, or a history of either condition, sensitivity and specificity was 100% and 14.2% 
respectively.107  In another study by Farah and McCullough involving 55 patients with an 
oral white mucosal lesion, sensitivity was again 100% while specificity was 0%.105  Unlike 
Ram and Siar who reported an accuracy of 80.6%, Farah reported an accuracy of only 
18.2%.105, 107  This considerable difference in accuracy is most likely attributed to the 
different sample population.105  A recent study by Awan et al. also reported high sensitivity 
and low specificity, with the values being 77.3% and 27.8% respectively.112  The lower 
sensitivity has been attributed to the sample population, which included a wider range of 
oral lesions than the two previous studies.112  In contrast, a recent study reported a 
sensitivity of 0% and specificity of 75.5%.113 In this study by Mehrotra et al., there were three 
dysplastic lesions and one cancerous lesion out of 102 patients examined with ViziLite – 
none of which had a positive ViziLite result.  Consequently, the NPV was very high, at 
94.8%, while PPV was 0%.113  Although not specified by the authors, the dysplastic and 
cancerous lesions may have been red, which is reportedly less preferentially highlighted by 
chemiluminescence than lesions with a white component.111, 112, 114  This may be due to the 
fact that erythroplakia has either atrophied epithelium or epithelium that has had no change 
in thickness, and that acetic acid does not enhance the refractile properties of 
erythroplakia.111  
Clearly, the ability to differentiate between keratotic, inflammatory, potentially malignant 
and malignant lesions is poor with ViziLite.105, 107, 111  Nevertheless, there are reports that 
ViziLite improves visualisation of lesions – particularly leukoplakias, although there are 
conflicting results.  Epstein et al. found a significant improvement in the brightness, 
sharpness and texture of lesions using ViziLite,114 while Kerr et al. noticed a significant 
improvement in only sharpness, a trend towards enhanced brightness, and no significant 
improvement in texture.111  Two other studies also noticed improved brightness and 
sharpness of oral lesions with chemiluminescence.112, 115  Visualisation of intraoral lesions 
was reportedly enhanced in Farah’s paper, however this was not statistically significant.105  
In contrast, visualisation can be more difficult due to an increase in mucosal surface 
reflectivity as a result of stimulated salivary flow following an acetic acid rinse.106, 111, 112  
Most studies have also found at least one new lesion that was not seen by COE;105, 106, 110, 111, 
114  however, the general consensus is that ViziLite does not provide any additional benefit 
to COE.105, 106, 113 
Although there have been several studies on ViziLite, the only published study assessing 
the efficacy of Microlux/DL as a diagnostic aid in visualising oral mucosal lesions is a 
prospective study by McIntosh et al.85  In this study, 50 patients referred to an oral medicine 
specialist unit because of an oral mucosal white lesion were examined by an oral medicine 
specialist.  Lesions were assessed clinically and were given a provisional diagnosis before 
undergoing incisional biopsy and histopathological analysis.  With a gold standard 
diagnostic test to compare to, sensitivity, specificity, PPV and NPV could be accurately 
assessed.  Results from this study found a sensitivity of 77.8%, a specificity of 70.7%, a PPV 
of 36.8% and a NPV of 93.5%.  These results indicate that while Microlux/DL is fairly good 
for highlighting potentially malignant oral mucosal lesions and the presence of no disease, 
the ability to differentiate between benign and malignant lesions is poor.  Furthermore, the 
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system did not find any new lesions, modify the provisional diagnosis, or change the biopsy 
site, although it did improve lesion visibility and border distinctness of the majority of 
lesions when compared to COE.  Furthermore, the emitted light from Microlux/DL was 
found to be very similar to a standard LED headlight.85  From these results alone, 
Microlux/DL does not appear to be a great benefit to COE, particularly since the sensitivity 
and specificity scores in this study are lower than Downer et al.’s calculated overall 
sensitivity and specificity for COE.84, 108 A limitation of the study was that a specialist 
performed the examinations rather than a general dental practitioner, and more trials are 
required to validate these findings in a general population.85 A significant finding however, 
was that examination of PMOLs with white light is more useful than standard incandescent 
or halogen light. 
More research is needed to support the use of chemiluminescence and tissue reflectance as 
an adjunct to COE.  The published papers on both ViziLite and Microlux/DL have flaws in 
their experimental design; the most common being the lack of a definitive diagnostic gold 
standard comparison (incisional biopsy and histopathology) for all lesions.106, 107, 110, 111, 114 To 
compensate, several studies used results from brush cytology as their main diagnostic 
comparison,106, 110, 114 but this does not provide a definitive diagnosis.5  Other weaknesses in 
studies include small sample size,85, 105, 107 recruiting patients from specialist clinics instead 
of from the general population,85, 105, 107, 111 and the use of specialists instead of general dental 
practitioners.85, 105, 111 As a consequence, results should be interpreted with caution as they 
cannot be generalised to general practitioners, nor to the general population where the 
prevalence of oral cancer and precancer is much lower.115 In addition, there was a potential 
for conflicts in interest in two studies.114, 115 Larger, well-designed clinical trials are required 
to determine the ability of these devices in improving the visualisation of potentially 
malignant lesions that cannot be identified by COE.5  
6.4 Tissue autofluorescence imaging (VELscope, Identafi) 
Another light-based adjunct to COE is a handheld device called a Visually Enhancing Lesion 
Scope (VELscope; LED Dental Inc., Burnaby, BC, Canada).  Using the idea that cellular 
fluorophores are excited by high intensity light of particular wavelengths, this device 
utilizes blue light 400 to 460 nm in wavelength to cause tissue autofluorescence.5 This 
technology is based on the fact that both the superficial epithelium and underlying stroma 
of developing premalignant lesions have changes in their optical properties.116  Normal oral 
epithelium appears pale green when directly viewed through a narrow-band filter, as green-
red fluorescence is excited from fluorophores in the oral tissues.1, 2, 5, 117 In contrast, 
dysplastic cells or potentially early tumours appear dark green to black due to the cellular 
and structural changes which occur in neoplastic tissue.1, 5, 117, 118 Cellular alterations such as 
decreased flavin adenine dinucleotide concentration and collagen matrix breakdown have 
been associated with loss of fluorescence visualisation (FV).117, 118 Furthermore, decreased 
fluorescence as a result of increased absorption and scattering of light occurs when there are 
structural changes in both the epithelium and lamina propria such as hypertrophy, 
hyperchromatism, cellular/nuclear pleomorphism and increased microvascularity.117, 118  
Being relatively new, the number of published literature about the efficacy of VELscope for 
visualising and detecting potentially malignant lesions is limited.  While the general 
consensus is that VELscope has very high sensitivity, the specificity has ranged quite 
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considerably depending on the study.  In three observational (cross-sectional) studies, the 
reported values for sensitivity ranged from 97% to 100% and for sensitivity, 80% to 100%.117-
119 In contrast, while Awan et al. had fairly high sensitivity, specificity was significantly 
lower.112  The reported sensitivity for dysplasia and leukoplakia/erythroplakia was 84.1% 
and 87.1% respectively, while the specificity was 15.3% and 21.4% respectively.112  Two 
recent studies have noted both low specificity and sensitivity with VELscope.113, 120  A cross-
sectional study by Mehrotra et al. found 50% sensitivity and 38.9% specificity after 
examining 156 patients seeking dental care with VELscope.113  More recently, a prospective 
study by Farah et al. reported a sensitivity of 30%, a specificity of 63% and an accuracy of 
55% when VELscope was used alone to examine 118 lesions from 112 patients.120  The large 
discrepancy for specificity in these studies is most likely attributed to the sample 
population.  Lane et al. and Poh et al. recruited patients with biopsy-confirmed oral 
dysplasia or SCC and Scheer et al. included patients with an increased risk of mucosal 
abnormalities.117-119 In contrast, Mehrotra et al. enrolled patients with lesions deemed 
clinically innocuous according to COE,113  while Farah et al. recruited patients with white or 
mixed white or red oral mucosal lesions,120  and in the study conducted by Awan et al., the 
only inclusion criteria was the presence of white, red and mixed white and red oral 
lesions.112  Only one study used VELscope in a private general dentistry practice.121 In this 
retrospective observational study, 905 patients were examined with VELscope.  The authors 
reported a 1.3% prevalence of mucosal abnormalities, with 83% of these lesions being 
potentially premalignant.121  When compared with results from incisional biopsies, studies 
demonstrated that VELscope could reveal high-risk lesions such as severe dysplasia and 
CIS; however, milder forms of dysplasia were not always detected.113, 117-119  Despite this, 
there are several published case studies of new lesions being uncovered with VELscope in 
patients with a history of epithelial dysplasia or CIS.122, 123  Furthermore, Farah et al. reported 
that VELscope revealed five lesions not found during COE, enhanced visualisation of 
34.74% of cases, changed the clinical provisional diagnosis of 22 lesions, and changed the 
biopsy site of four lesions.120  Border distinctness and visibility of benign and dysplastic 
lesions, however, were not different.120  VELscope may also play a role with reducing the 
risk of tumour recurrence as it can be used before the excision of lesions to delineate 
malignant and premalignant subclinical extensions.118 
A high number of false positives with VELscope resulted in low specificity and PPV values, 
with reported PPV ranging from 6.4% to 54.5%, while NPV ranged from 97.5% to 100%.113, 
119, 120  Inflammatory and traumatic lesions such as oral lichen planus, granulation tissue, 
chronic inflammation, ulcerations and hyperkeratosis had loss of FV and were therefore 
false positive results.119  These tissues displayed less autofluorescence as they also had 
increased submucosal blood flow, altered metabolic activity and structural changes.113, 119  
To discriminate inflammatory lesions from dysplastic lesions, soft pressure should be 
applied to reduce blood flow to the area.120  Blanched inflammatory lesions will have normal 
autofluorescence whereas potentially malignant and malignant lesions remain 
unchanged.113, 119-122  However, applied pressure to dysplastic and OSCC lesions can still 
cause blanching, even though these lesions had loss of fluorescence.120  Interestingly, one 
study found a gain of autofluorescence in verrucous leukoplakias that had no dysplasia.119  
From this, the authors proposed that invasive carcinomas will also have a gain in 
autofluorescence and therefore, loss of fluorescence would not be an applicable indicator for 
malignancy in verrucous lesions.119 Nonetheless, Balevi calculated, using Bayes’ theorem 
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and the sensitivity and specificity values from existing literature, a PPV of 1.27% and a false 
positive rate of 98.63% if VELscope was used to routinely screen the total population for oral 
cancer.124  The author concluded that as VELscope has such a high misdiagnosis rate in the 
general population, the use of VELscope should be limited to oral cancer specialist clinics 
where the prevalence of oral cancer is most likely greater than 10%.124  
It is clear that there is currently an insufficient body of evidence to support the use of 
VELscope as an adjunct to COE for oral cancer screening in general practice.  While 
VELscope does show promise, it cannot differentiate inflammatory and traumatic lesions 
from premalignant and malignant lesions.  Therefore, use of the device requires skill and 
training in order to interpret results.113, 119, 120  With low specificity, the clinician still needs to 
conduct a thorough examination and use their clinical judgement as well as the patient’s 
history to determine the need for further investigation,120 otherwise, there will be an 
increased risk of overtreatment and a higher number of unnecessary referrals.112  Most 
published studies on VELscope have a small sample population that is not representative of 
the general population – namely, they were patients with a history of potentially malignant 
and malignant oral lesions.117-120, 122, 123  In addition, a major limitation of VELscope is that 
the difference between loss of fluorescence and diminished fluorescence is subjective and 
depends on the experience of the user.112, 119  When this is compounded with specialists who 
were not blinded,117, 118  it is possible that results may have been overestimated.  
Consequently, the results from current literature cannot be applied to the general 
population and general practitioners.  Until larger, blinded, randomized-controlled clinical 
trials can evaluate the performance of VELscope in populations where the prevalence for 
oral cancer is low, the use of this device should be restricted to specialist oral cancer clinics. 
It is possible that the newest oral cancer screening system on the market, Identafi 
(previously marketed as Identafi 3000 ultra; DentalEZ Group, Malvern, PA, USA), may 
show more potential than its light-based screening predecessors.  Identafi utilizes both 
optical autofluorescence and reflectance spectroscopy, in addition to traditional white light, 
to screen for PMOLs and OSCC.86 According to the manufacturer, areas with biochemical 
and morphological changes in cells can be visually identified by exciting oral tissues using a 
combination of multi-spectral light.86 Although highly concentrated white light may be 
considered slightly better for visualising oral lesions than incandescent operatory lights,85 it 
cannot be used alone as it is still difficult to differentiate premalignant lesions with 
inflammation, oral lichen planus/lichenoid reactions and other benign conditions which 
clinically appear similar to precancer.125 Consequently, the device also employs violet and 
green-amber light for detecting changes in fluorescence and reflectance respectively, thereby 
making it possible to locate areas of diseased tissue.86 
Unlike VELscope which uses blue light, Identafi uses violet light to excite tissues and induce 
fluorescence.86 As dysplastic and cancerous tissues have lower blue-green fluorescence 
intensity than normal tissues when they are excited by light with wavelengths between 330 
to 470 nm,116 abnormal tissues should appear dark brown or black when exposed to the 405 
nm violet light emitted by Identafi.86 A study by Roblyer et al. found that the optimal 
excitation wavelength of light for discriminating normal tissue from dysplasia and invasive 
cancer is 405 nm.125 At this wavelength, the authors reported a sensitivity of 95.9% to 100% 
and a specificity of 91.4% to 96.2% for differentiating dysplasia and cancer from normal 
tissue.125  Based on these results, it can be expected that Identafi may have similar values for 
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sensitivity and specificity.  A recent case report illustrated how autofluorescence tissue 
imaging with Identafi aided in diagnosing a metastatic tumour that was clinically 
innocuous.126 Furthermore, an unpublished study by Zuluaga et al. involving 120 patients 
from four clinical centres found that the violet light had 100% NPV and a PPV nearing 60% 
for differentiating between normal and dysplastic or malignant tissue in one cohort.127  The 
other cohorts had similar findings, and the authors expect that the overall PPV will be 
improved in the entire cohort with the addition of green-amber light.127  
Tissue reflectance can be enhanced with the addition of green-amber light (dominant 545 
nm).86, 127 Although the haemoglobin absorption is strongest at 420 nm,128  this light can 
delineate the vasculature of lesions from surrounding normal tissues as its wavelength is 
close to one of the two primary bands of haemoglobin absorption (Q-band peak of 542 
nm).86, 128 Premalignant and malignant tissues will appear diffuse due to their disorganised 
growth of blood vessels.86 Therefore, as abnormal signs of morphologic changes can be 
highlighted, the addition of this light is expected to reduce the rate of false positives.86, 127 
However, further research is required to determine the efficacy of a multispectral system 
like Identafi. 
7. Conclusions 
Morbidity and mortality rates for oral cancer can be improved if potentially malignant oral 
mucosal lesions are found before they reach an advanced stage. Investigation of socio 
demographic factors in relation to patient delay is an important area deserving of further 
attention. Themes have emerged through the use of qualitative studies regarding barriers 
and triggers to patient presentation. Drawing upon the triggers associated with help seeking 
behavior and creating awareness of the symptoms of oral cancer may allow patients to 
attribute their signs to something more serious. Educational interventions and self screening 
promotion aimed at the population have the potential to create awareness of oral cancer. 
Patients have stated that if they were more aware of oral cancer, they would have presented 
sooner regarding their signs and symptoms. As it has been shown that patients often tell a 
family member or friend about their symptoms, increased knowledge among the public 
may ensure that the patient is advised to seek help by their loved ones. Educational 
interventions should also be targeted at pharmacists, as their advice has the potential to 
decrease patient delay should a patient seek advice from a pharmacy.  
Dentists should be performing opportunistic screening on patients at dental appointments; 
however this is not happening consistently. Lack of confidence signals the need for further 
training, which can be done at both the undergraduate level and following graduation in the 
form of continuing professional development. As patients will commonly present to their 
doctor regarding an oral lesion, continuing education courses should also be made available 
for doctors. Identification of risk factors and effective patient counseling has the potential to 
decrease the incidence of oral cancer and there is need for improvement in this area. Risk 
factor analysis and effective communication could be integrated into continuing education 
courses. Practitioners should be more involved in creating awareness of oral cancer and this 
may be as simple as making pamphlets available at their surgeries.  
Problems exist with interpreting data from many studies performed in this area. Often 
studies are performed retrospectively, thus incorporating memory bias or relying on records 
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which may be incomplete. The low incidence of oral cancer renders sample sizes small, 
making it difficult to generalize the results. Continued investigation of the barriers and 
triggers to help seeking behavior and identification of factors involved in professional delay 
is required in order to inform effective interventions. 
Although many new diagnostic aids are available to help clinicians detect oral mucosal 
lesions earlier, the current screening devices and methods are limited by their inability to 
detect and discriminate between benign and malignant lesions, and thus cannot be used 
alone as an alternative to COE – they must be used as an adjunct.  As skill and training are 
required in order to interpret results, the use of these devices and methods should be 
limited to specialist centres and experienced and trained clinicians, if they are to be 
recommended for use at all.  Currently, there is still insufficient evidence to support the use 
of vital tissue staining and technology based on tissue reflectance and autofluorescence, 
particularly since none have consistently shown that they are more effective than COE.   
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